Nanostructured lipid carriers based nanogel for meloxicam delivery: mechanistic, in-vivo and stability evaluation

References

• Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib. Drug Dev Ind Pharm 2006;32:911–18
   PubMed Web of Science ®Google Scholar
• Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54:S131–55
   PubMed Web of Science ®Google Scholar
• Schafer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 2007;59:427–43
   PubMed Web of Science ®Google Scholar
• Burke A, Smyth E, FitzGerald GA. Analgesic-anti pyretic and anti inflammatory agents; pharmacotherapy of gout. In: Bruntom LL, Lazo JS, Parker KL, eds. Goodman's and Gilman's the pharmacological basis of therapeutics. New York: McGraw Hill; 2006: 676–700
   Google Scholar
• Abramson SB, Yazici Y. Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv Drug Deliv Rev 2006;58:212–25
   PubMed Web of Science ®Google Scholar
• Quan LD, Thiele GM, Tian J, Wang D. The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat 2008;18:723–38
   PubMed Web of Science ®Google Scholar
• Yuan Y, Li S, Mo F, Zhong D. Investigation of microemulsion system for transdermal delivery of meloxicam. Int J Pharm 2006;32:1117–23
   Google Scholar
• Jantharaprapap R, Stagni G. Effects of penetration enhancers on in-vitro permeability of meloxicam gels. Int J Pharm 2007;343:26–33
   PubMed Web of Science ®Google Scholar
• Ruiz Martinez MA, Lopez-Viota Gallardo J, de Benavides MM, et al. Rheological behavior of gels and meloxicam release. Int J Pharm 2007;333:17–23
   PubMed Web of Science ®Google Scholar
• Yuan Y, Chen X, Zhong D. Determination of meloxicam in human plasma by liquid chromatography–tandem mass spectrometry following transdermal administration. J Chromatogr 2007;B852:650–4
   Google Scholar
• Yuan Y, Li S, Yu L, et al. Physicochemical properties and evaluation of microemulsion systems for transdermal delivery of meloxicam. Chem Res Chin Univ 2007;23:81–6
   Web of Science ®Google Scholar
• Kasliwal N, Derle D, Negi J, Gohil K. Effect of permeation enhancers on the release and permeation kinetics of meloxicam gel formulations through rat skin. Asian J Pharm Sci 2008;3:3193–9
   Google Scholar
• Ah YC, Choi JK, Choi YK, et al. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. Int J Pharm 2010;385:12–19
   PubMed Web of Science ®Google Scholar
• Khurana S, Bedi PMS, Jain NK. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci 2013;93:763–72
   PubMed Web of Science ®Google Scholar
• Utreja S, Khopade AJ, Jain NK. Lipoprotein-mimicking biovectorized systems for methotrexate delivery. Pharm Acta Helv 1999;73:275–9
   PubMedGoogle Scholar
• Khurana S, Bedi PMS, Jain NK. Development of nanostructured lipid carriers (NLC) for controlled delivery of meloxicam. Int J Biomed Nanosci Nanotechnol 2010;1:247–66
   Google Scholar
• Khurana S, Bedi PMS, Jain NK. Development of nanostructured lipid carriers (NLC) for controlled delivery of mefenamic acid. Int J Biomed Nanosci Nanotechnol 2012;2:232–50
   Google Scholar
• Dubey V, Mishra D, Dutta T, et al. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007;123:148–54
   PubMed Web of Science ®Google Scholar
• Stahl J, Niedorf F, Kietzmann M. Characterisation of epidermal lipid composition and skin morphology of animal skin ex vivo. Eur J Pharm Biopharm 2009;72:310–16
   PubMed Web of Science ®Google Scholar
• Xi H, Cun D, Xiang R, et al. Intra-articular drug delivery from an optimized topical patch containing teriflunomide and lornoxicam for rheumatoid arthritis treatment: does the topical patch really enhance a local treatment? J Control Release 2013;169:73–81
   PubMed Web of Science ®Google Scholar
• Organization for Economic Cooperation and Development (OECD). Guidelines for testing chemicals 410 repeated dose dermal toxicity: 21/28-day study. Paris: OECD; 1981
   Google Scholar
• Lee BJ, Lee TS, Cha BJ, et al. Percutaneous absorption and histopathology of a poloxamer-based formulation of capsaicin analog. Int J Pharm 1997;159:105–14
   Web of Science ®Google Scholar
• Organization for Economic Cooperation and Development (OECD) Guidelines. Test guideline 404 acute dermal irritation/corrosion. Paris: OECD; 2002
   Google Scholar
• Manosroi A, Chankhampan C, Manosroi W, Manosroi J. Transdermal absorption enhancement of papain loaded in elastic niosomes incorporated in gel for scar treatment. Eur J Pharm Sci 2013;48:474–83
   PubMed Web of Science ®Google Scholar
• ICH Stability testing of new drug substances and products. International Conference on Harmonization (ICH) Guidelines Q1A (R2). European Medicines Agency, CPMP/ICH/2736/99; 2003
   Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Junyaprasert VB, Teeranachaideekul V, Souto EB, et al. Q10-loaded NLC versus nanoemulsions: stability rheology and in vitro skin permeation. Int J Pharm 2009;377:207–14
   PubMed Web of Science ®Google Scholar
• Freitas C, Muller RH. Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencapsul 1999;16:59–71
   PubMed Web of Science ®Google Scholar
• Chen H, Chang, X, Du D, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006;110:296–306
   PubMed Web of Science ®Google Scholar
• Teeranachaideekul V, Boonme P, Souto EB, et al. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J Control Release 2008;128:134–41
   PubMed Web of Science ®Google Scholar
• Williams AC, Barry BW. Penetration enhancers. Adv Drug Del Rev 2004;56:603–18
   PubMed Web of Science ®Google Scholar
• Fox LT, Gerber M, Plessis JD, Hamman JH. Transdermal drug delivery enhancement by compounds of natural origin. Mol 2011;16:10507–40
   Web of Science ®Google Scholar
• Shah PP, Desai PR, Patel AR, et al. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials 2012;33:1607–17
   PubMed Web of Science ®Google Scholar
• Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 1991;24:1–26
   PubMedGoogle Scholar
• Babita K, Kumar V, Rana V, et al. Thermotropic and spectroscopic behavior of skin: relationship with percutaneous permeation enhancement. Curr Drug Deliv 2006;3:95–113
   PubMedGoogle Scholar
• Karadzovska D, Brooks JD, Monteiro-Rivierem NA, Riviere JE. Predicting skin permeability from complex vehicles. Adv Drug Deliv Rev 2013;65:265–77
   PubMed Web of Science ®Google Scholar
• Elias PM, Cooper ER, Korc A, Brown BE. Percutaneous transport in relation to stratum corneum structure and lipid composition. J Invest Dermatol 1981;76:297–301
   PubMed Web of Science ®Google Scholar
• Kostiuk NV, Zhigulina VV, Belyakova MB, et al. Effect of melatonin on lipid barrier in rats' skin. Am J Biochem 2012;2:67–73
   Google Scholar
• Han F, Yin R, Che X, et al. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design characterization and in vivo evaluation. Int J Pharm 2012;439:349–57
   PubMed Web of Science ®Google Scholar
• Chen-yu G, Chun-fen Y, Qi-lu L, et al. Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm 2012;430:292–8
   PubMed Web of Science ®Google Scholar
• Distel M, Mueller C, Bluhmkij E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996;35:68–77
   PubMedGoogle Scholar
• Lanes SF, Rodriguez LA, Hwang GE. Baseline risk of gastrointestinal disorders among new users of meloxicam ibuprofen diclofenac naproxen and indomethacin. Pharmacoepidemiol Drug Saf 2000;9:113–17
   PubMed Web of Science ®Google Scholar
• Villegas I, Alarcon de la, Lastra C, et al. Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats. Eur J Pharmacol 2001;414:79–86
   PubMed Web of Science ®Google Scholar